• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用 Ultrahuman M1 连续血糖监测平台对非糖尿病和糖尿病前期印度人群进行代谢健康跟踪:一项多臂观察性研究。

Metabolic health tracking using Ultrahuman M1 continuous glucose monitoring platform in non- and pre-diabetic Indians: a multi-armed observational study.

机构信息

Ultrahuman Healthcare Private Limited, No. 799, V K Paradise Sector2, HSR Layout Bengaluru, Bangalore, Karnataka, 560102, India.

出版信息

Sci Rep. 2024 Mar 18;14(1):6490. doi: 10.1038/s41598-024-56933-2.

DOI:10.1038/s41598-024-56933-2
PMID:38499685
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10948749/
Abstract

Continuous glucose monitoring (CGM) device adoption in non- and pre-diabetics for preventive healthcare has uncovered a paucity of benchmarking data on glycemic control and insulin resistance for the high-risk Indian/South Asian demographic. Furthermore, the correlational efficacy between digital applications-derived health scores and glycemic indices lacks clear supportive evidence. In this study, we acquired glycemic variability (GV) using the Ultrahuman (UH) M1 CGM, and activity metrics via the Fitbit wearable for Indians/South Asians with normal glucose control (non-diabetics) and those with pre-diabetes (N = 53 non-diabetics, 52 pre-diabetics) for 14 days. We examined whether CGM metrics could differentiate between the two groups, assessed the relationship of the UH metabolic score (MetSc) with clinical biomarkers of dysglycemia (OGTT, HbA1c) and insulin resistance (HOMA-IR); and tested which GV metrics maximally correlated with inflammation (Hs-CRP), stress (cortisol), sleep, step count and heart rate. We found significant inter-group differences for mean glucose levels, restricted time in range (70-110 mg/dL), and GV-by-SD, all of which improved across days. Inflammation was strongly linked with specific GV metrics in pre-diabetics, while sleep and activity correlated modestly in non-diabetics. Finally, MetSc displayed strong inverse relationships with insulin resistance and dysglycemia markers. These findings present initial guidance GV data of non- and pre-diabetic Indians and indicate that digitally-derived metabolic scores can positively influence glucose management.

摘要

连续血糖监测(CGM)设备在非糖尿病和糖尿病前期患者中的采用,揭示了针对高风险印度/南亚人群的血糖控制和胰岛素抵抗的基准数据不足。此外,数字应用程序衍生的健康评分与血糖指数之间的相关性效力缺乏明确的支持证据。在这项研究中,我们使用 Ultrahuman(UH)M1 CGM 获得了血糖变异性(GV),并通过 Fitbit 可穿戴设备获得了活动指标,用于研究血糖正常控制(非糖尿病)的印度/南亚人和有糖尿病前期(N = 53 名非糖尿病患者,52 名糖尿病前期患者)的患者,为期 14 天。我们检查了 CGM 指标是否可以区分两组,评估了 UH 代谢评分(MetSc)与血糖异常(OGTT、HbA1c)和胰岛素抵抗(HOMA-IR)的临床生物标志物的关系;并测试了哪些 GV 指标与炎症(Hs-CRP)、压力(皮质醇)、睡眠、步数和心率的相关性最强。我们发现两组之间的平均血糖水平、限制在范围内的时间(70-110mg/dL)和 GV 标准差存在显著差异,所有这些指标都在几天内有所改善。炎症与糖尿病前期患者的特定 GV 指标密切相关,而睡眠和活动在非糖尿病患者中相关性较弱。最后,MetSc 与胰岛素抵抗和血糖异常标志物呈强烈的负相关。这些发现为非糖尿病和糖尿病前期的印度人提供了初步的 GV 数据指导,并表明数字衍生的代谢评分可以积极影响血糖管理。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4235/10948749/0197ccf41ad1/41598_2024_56933_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4235/10948749/4e77bc7b2ecf/41598_2024_56933_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4235/10948749/69678cb80e14/41598_2024_56933_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4235/10948749/0197ccf41ad1/41598_2024_56933_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4235/10948749/4e77bc7b2ecf/41598_2024_56933_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4235/10948749/69678cb80e14/41598_2024_56933_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4235/10948749/0197ccf41ad1/41598_2024_56933_Fig3_HTML.jpg

相似文献

1
Metabolic health tracking using Ultrahuman M1 continuous glucose monitoring platform in non- and pre-diabetic Indians: a multi-armed observational study.使用 Ultrahuman M1 连续血糖监测平台对非糖尿病和糖尿病前期印度人群进行代谢健康跟踪:一项多臂观察性研究。
Sci Rep. 2024 Mar 18;14(1):6490. doi: 10.1038/s41598-024-56933-2.
2
Continuous Glucose Monitoring for Prediabetes: What Are the Best Metrics?连续血糖监测用于糖尿病前期:最佳指标是什么?
J Diabetes Sci Technol. 2024 Jul;18(4):835-846. doi: 10.1177/19322968241242487. Epub 2024 Apr 17.
3
Glucose Variability Assessed with Continuous Glucose Monitoring: Reliability, Reference Values, and Correlations with Established Glycemic Indices-The Maastricht Study.使用连续血糖监测评估血糖变异性:可靠性、参考值以及与既定血糖指标的相关性——马斯特里赫特研究。
Diabetes Technol Ther. 2020 May;22(5):395-403. doi: 10.1089/dia.2019.0385. Epub 2020 Jan 17.
4
Non-invasive wearables for remote monitoring of HbA1c and glucose variability: proof of concept.用于远程监测 HbA1c 和血糖变异性的非侵入性可穿戴设备:概念验证。
BMJ Open Diabetes Res Care. 2021 Jun;9(1). doi: 10.1136/bmjdrc-2020-002027.
5
Glycemic variability in nondiabetic morbidly obese persons: results of an observational study and review of the literature.非糖尿病病态肥胖人群的血糖变异性:一项观察性研究结果及文献综述
J Diabetes Sci Technol. 2014 Sep;8(5):1042-7. doi: 10.1177/1932296814537039. Epub 2014 May 29.
6
Glycemic variability assessed using continuous glucose monitoring in individuals without diabetes and associations with cardiometabolic risk markers: A systematic review and meta-analysis.使用连续血糖监测评估无糖尿病个体的血糖变异性及其与心血管代谢风险标志物的相关性:系统评价和荟萃分析。
Clin Nutr. 2024 Apr;43(4):915-925. doi: 10.1016/j.clnu.2024.02.014. Epub 2024 Feb 22.
7
Measures of Glycemic Variability in Type 1 Diabetes and the Effect of Real-Time Continuous Glucose Monitoring.1 型糖尿病的血糖变异性衡量指标及实时连续血糖监测的影响。
Diabetes Technol Ther. 2016 Dec;18(12):806-812. doi: 10.1089/dia.2016.0146.
8
Pre-Diabetics with Hypovitaminosis D Have Higher Risk for Insulin Resistance.维生素D缺乏的糖尿病前期患者发生胰岛素抵抗的风险更高。
Clin Lab. 2019 May 1;65(5). doi: 10.7754/Clin.Lab.2018.181014.
9
Clinical and Lifestyle Determinants of Continuous Glucose Monitoring Metrics in Insulin-Treated Patients with Type 2 Diabetes Mellitus.2 型糖尿病胰岛素治疗患者连续血糖监测指标的临床和生活方式决定因素。
Diabetes Metab J. 2023 Nov;47(6):826-836. doi: 10.4093/dmj.2022.0273. Epub 2023 Aug 24.
10
Evaluation of the relationship between cardiac autonomic function and glucose variability and HOMA-IR in prediabetes.评价心脏自主神经功能与血糖变异性及 HOMA-IR 在糖尿病前期的关系。
Diab Vasc Dis Res. 2020 May-Jun;17(5):1479164120958619. doi: 10.1177/1479164120958619.

引用本文的文献

1
Integrating Precision Medicine and Digital Health in Personalized Weight Management: The Central Role of Nutrition.将精准医学和数字健康整合到个性化体重管理中:营养的核心作用。
Nutrients. 2025 Aug 20;17(16):2695. doi: 10.3390/nu17162695.

本文引用的文献

1
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17).印度代谢性非传染性疾病健康报告:ICMR-INDIAB 国家横断面研究(ICMR-INDIAB-17)。
Lancet Diabetes Endocrinol. 2023 Jul;11(7):474-489. doi: 10.1016/S2213-8587(23)00119-5. Epub 2023 Jun 7.
2
Expert Consensus Recommendations on Time in Range for Monitoring Glucose Levels in People with Diabetes: An Indian Perspective.糖尿病患者血糖水平监测的血糖达标时间专家共识建议:印度视角
Diabetes Ther. 2023 Feb;14(2):237-249. doi: 10.1007/s13300-022-01355-4. Epub 2023 Jan 27.
3
Use of Continuous Glucose Monitors by People Without Diabetes: An Idea Whose Time Has Come?
《无糖尿病患者使用连续血糖监测仪:时机已到?》
J Diabetes Sci Technol. 2023 Nov;17(6):1686-1697. doi: 10.1177/19322968221110830. Epub 2022 Jul 20.
4
Association of Serum High Sensitivity C-Reactive Protein With Pre-diabetes in Rural Population: A Two-Year Cross-Sectional Study.农村人群血清高敏C反应蛋白与糖尿病前期的关联:一项为期两年的横断面研究。
Cureus. 2021 Oct 28;13(10):e19088. doi: 10.7759/cureus.19088. eCollection 2021 Oct.
5
Associations Between Device-Measured Physical Activity and Glycemic Control and Variability Indices Under Free-Living Conditions.在自由生活条件下,设备测量的身体活动与血糖控制和变异性指标之间的关联。
Diabetes Technol Ther. 2022 Mar;24(3):167-177. doi: 10.1089/dia.2021.0294. Epub 2021 Dec 14.
6
Screening for Diabetes and Prediabetes.糖尿病与糖尿病前期的筛查。
Endocrinol Metab Clin North Am. 2021 Sep;50(3):369-385. doi: 10.1016/j.ecl.2021.05.002. Epub 2021 Jul 12.
7
Improvement in Glucose Regulation Using a Digital Tracker and Continuous Glucose Monitoring in Healthy Adults and Those with Type 2 Diabetes.使用数字追踪器和持续葡萄糖监测改善健康成年人及2型糖尿病患者的血糖调节
Diabetes Ther. 2021 Jul;12(7):1871-1886. doi: 10.1007/s13300-021-01081-3. Epub 2021 May 28.
8
Technology in the management of type 2 diabetes: Present status and future prospects.技术在 2 型糖尿病管理中的应用:现状与展望。
Diabetes Obes Metab. 2021 Aug;23(8):1722-1732. doi: 10.1111/dom.14418. Epub 2021 May 20.
9
Glycemic improvement with a novel interim intervention technique using retrospective professional continuous glucose monitoring (GLITTER study): A study from Mumbai, India.使用回顾性专业连续血糖监测的新型临时干预技术改善血糖:来自印度孟买的一项研究。
Diabetes Metab Syndr. 2021 May-Jun;15(3):703-709. doi: 10.1016/j.dsx.2021.03.011. Epub 2021 Mar 20.
10
3. Prevention or Delay of Type 2 Diabetes: .3. 2 型糖尿病的预防或延迟: 。
Diabetes Care. 2021 Jan;44(Suppl 1):S34-S39. doi: 10.2337/dc21-S003.